IL6 and cancer: Treatment with a novel Fc-VEGF chimeric antibody drug (Fc-VFD) inhibits the secretion of pro-angiogenic factors VEGF-A and IL-6 by cancer cells in TME, suppressing excessive angiogenesis and overcoming hypoxia resistance in cancer cells.